rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 79 80 81 82 83 ... 140 »» | Laatste | Omlaag ↓
  7. [verwijderd] 14 mei 2007 12:26

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0




    http://www.genengnews.com/articles/chitem.aspx?aid=2086

    >>
    Cell Culture Landscape Changes Rapidly

    Genetic Engineering & Biotechnology News
    May 1, 2007
    By Steven Heffner

    Growth in biopharmaceuticals is creating an unprecedented increase in demand for cell culture products. Cell culture techniques have been used in biological sciences for more than 50 years; however, cell culture applied to production systems has been around for only half that time. The cell culture industry, which began in the late 1980s from the utilization of recombinant DNA technology and cell hybridization, is, today, a major underpinning of the biopharmaceutical market.

    Media, sera, and reagents are the fuel that powers these cell culture manufacturing engines, and suppliers are beginning to see sales ramping up accordingly. According to Kalorama’s Cell Culture: The World Market for Media, Sera, and Reagents, the market for these products is growing at an annual rate in excess of 12% and headed for more than $2.6 billion in 2011.

    Changing Market Drivers

    At the same time that demand for these products is increasing, the demand is also changing. Traditional sera products are stagnant, and, increasingly, researchers and process engineers are demanding products with more rigid controls over ingredients. The emergence of serum-free media and chemically defined media shows the increasing trend toward stringent component control, which has characterized the past few years of product development.

    However, more change is on the horizon. Biomedical research at the basic levels will become a major driver of innovation for the cell culture market. Biomedical research and bioprocessing have a wide range of supply needs, including high-quality media and reagents for fermentation and cell culture. In cell biology research, cell screening technology has proved to be important in finding high-producing cell lines, and research is now focused on how to predict growth characteristics of cells at an earlier stage. Progress in the future will come from processes, such as metabolic engineering, that will aid in improving cell lines, which will continue to be a main focal point of research.

    Stem Cell Research

    Along these same lines, stem cell research will also add to the robust growth of the cell culture market. The growing use and diverse applications of stem cells are having a significant impact on the media market, as companies work to understand how best to optimize and influence their growth. For stem cell applications, serum-free media that lack growth factors, cytokines, or artificial stimulators of proliferation will play an increasingly important role.

    The expected growth in the stem cell market provides a tremendous growth opportunity. Kalorama estimates that stem cell research accounted for nearly $1 billion million in expenditures last year, 10% of which was allocated to consumables, and about 5% of the consumable allocation was spent on media and other cell culture supplies. In addition, media and serum used in stem cell research are priced higher than similar, non-stem cell products.

    Multiple licensing agreements and acquisitions have been made in the cell culture market by numerous companies in order to secure a foothold in the stem cell supply market .

    Vaccine Production

    Another important driver of the cell culture market will be the production of seasonal influenza vaccines, as well as pandemic vaccine candidates. The next generation of seasonal influenza and pandemic vaccines will be produced by cell culture-based technology. This trend bodes well for the continued growth of the cell culture market.

    The traditional method of manufacturing influenza vaccines has been through egg-based technology. However, due to the sheer quantity of vaccines that may be needed in the future, both for seasonal influenza and pandemic influenza, there is a move away from egg-based systems. Cell-based vaccine production dramatically reduces the possibility for contamination and promises to be a more reliable, flexible, and expandable platform than egg-based methods.

    While both methods could produce an equally effective vaccine against a virus, egg-based production is physically limited by the availability of specialized eggs and alone may not be able to meet the accelerated demands of a global influenza pandemic. Cell-based technology offers many benefits over egg-based production, including scalability, production risk mitigation (In the case of an avian flu pandemic, egg-producing flocks could decline, jeopardizing vaccine production capabilities.), speed of development (manufacturers are able to bypass the steps needed to adapt the virus strains to grow in eggs), and hypoallergenicity.

    The U.S. government has been encouraging manufacturers to develop cell-based flu vaccine methods in recent years. The National Institute of Allergy and Infectious Diseases (NIAID) supports a research program to advance the development of cell culture technologies to improve and modernize the production of influenza vaccines. Between fiscal years 1998 and 2005, NIAID’s support for research for cell culture technology totaled approximately $35 million, according to the Department of Health and Human Services (HHS).

    In addition, in March 2005 the HHS awarded a five-year contract to Sanofi Pasteur for $97 million to develop cell-based influenza vaccine technology, with the goal of obtaining the FDA license for a vaccine. In September 2006, Sanofi Pasteur announced that it had completed a clinical trial of its cell culture-based seasonal influenza vaccine and demonstrated the production-scale potential of a cell line in a successful bioreactor run of 20,000 L.

    In October 2005, Chiron initiated a Phase I/II study of an investigational cell culture–derived influenza vaccin
  12. [verwijderd] 14 mei 2007 20:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    dr ligt veel ijs in zowel d boed als de laat.........dus dr gebeurt geenfluit. Ze dromken een glas, deden een plas en lieten het zoals het was.
  13. [verwijderd] 14 mei 2007 20:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    pff door de 1.20 heen? Er zijn totaal geen kopers behalve die ene die dezelfde aantallen op 1.16/1.17 koop/verkoopt.Hopelijk gaat het hier om een computer,zou dit werkelijk een persoon zijn dan heeft die wel het meest troosteloze beroep ter wereld.
  14. [verwijderd] 14 mei 2007 20:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    zijn pc volgens mij..en laten dan ook nog de helft zien...zal wel met verschillende brokers te maken hebben.

    ligt we lekker stevig in deze roerige tijden.
  18. [verwijderd] 14 mei 2007 21:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Alle seinen op groen ja :

    http://moneycentral.msn.com/investor/StockRating/srsmain.asp?
    Symbol:GTCB
    Date:5/11/2007
    Buy Rating:4.5
    Sell Rating:0
    Open:1.16
    Close:1.16
    Support:1.10
    Resistance:1.21


  21. [verwijderd] 15 mei 2007 17:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Quick SummaryDetails GTCB :

    ProEarnings growth in the past year is holding steady compared to earnings growth in the past three years. NeutralPrevious day's closing price for GTCB was slightly above its 50-day moving average. PositiveOne or more analysts has modestly increased quarterly earnings estimates for GTCB. PositiveConThe price-to-sales multiple is significantly higher than the average for all stocks in the StockScouter universe. Negative for a small company like GTCB
2.783 Posts
Pagina: «« 1 ... 79 80 81 82 83 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.070
AB InBev 2 5.518
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.730
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.747
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.753
Aedifica 3 916
Aegon 3.258 322.870
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.894
Agfa-Gevaert 14 2.051
Ahold 3.538 74.340
Air France - KLM 1.025 35.057
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.912
Allfunds Group 4 1.475
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.334
AMG 971 133.664
AMS 3 73
Amsterdam Commodities 305 6.696
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.011
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.784
Arcelor Mittal 2.033 320.741
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.240
ASML 1.766 107.945
ASR Nederland 21 4.500
ATAI Life Sciences 1 7
Atenor Group 1 495
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.681
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.403